Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

ClinicalTrials.gov ID: NCT00665626

Public ClinicalTrials.gov record NCT00665626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.

Study identification

NCT ID
NCT00665626
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rigel Pharmaceuticals
Industry
Enrollment
219 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2008
Primary completion
May 31, 2009
Completion
May 31, 2009
Last update posted
Apr 30, 2017

2008 – 2009

United States locations

U.S. sites
27
U.S. states
16
U.S. cities
27
Facility City State ZIP Site status
Arthritis & Rheumatic Disease Specialties Aventura California 33180
Desert Medical Advances Palm Desert California 92260
San Diego Arthritis & Medical Clinic San Diego California 92108
Department of Rheumatology Washington D.C. District of Columbia 20010
RASF-Clinical Research Center Boca Raton Florida 33486
Florida Medical Research Institute Gainsville Florida 32607
Paddock Park Clinical Research Ocala Florida 34474
Lovelace Scientific Resources Sarasota Florida 34233
Intermountain Orthopedics Boise Idaho 83702
Rheumatology Associates, SC Chicago Illinois 60612
Memorial Medical Group Clinical Research Inst South Bend Indiana 46601
Center for Arthritis & Osteoperosis Elizabethtown Kentucky 42701
The Osteoporosis & Clinical Trials Center Cumberland Maryland 21502
The Osteoporosis & Clinical Trials Center Hagerstown Maryland 21740
Fiechtner Research, Inc. Lansing Michigan 48910
Westroads Medical Group Omaha Nebraska 68114
North Shore Long Island Jewich Health System Lake Success New York 11042
Andrew Porges, MD PC Roslyn New York 11576
Rheumatology Associates of Long Island Smithtown New York 11787
Clinical Research Division Mayfield Village Ohio 44143
Health Research of Oklahoma Oklahoma City Oklahoma 73103
Rheumatology Associates Erie Pennsylvania 16508
Clinical Research Center of Reading, LLP West Reading Pennsylvania 34474
Rheumatic Disease Associates Willow Grove Pennsylvania 19090
Austin Rheumatology & Research Austin Texas 78705
Houston Institute for Clinical Research Houston Texas 77074
Arthritis Northwest, PLLC Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00665626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00665626 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →